
During 2014 Danish biotech company Veloxis will receive a crucial verdict, as the company can expect the final decision in a review that the EMA has just agreed to initiate.
Tuesday evening Veloxis announced that EMA has begun review of the company’s marketing authorization application (MAA) for LCP-Tacro for the prevention of organ rejection in kidney transplant patients in the European Union.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app